Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis

This publication has 31 references indexed in Scilit:

• Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers
  Biochemical Pharmacology, 2015
• Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice
  Clinical Rheumatology, 2015
• The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study
  Annals of the Rheumatic Diseases, 2014
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
  Annals of the Rheumatic Diseases, 2014
• A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
  Seminars in Immunology, 2014
• Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis
  The Pharmacogenomics Journal, 2012
• Biopatología de la membrana sinovial en la artritis psoriásica
  Reumatología Clínica, 2012
• Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0
  Annals of the Rheumatic Diseases, 2012
• Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register
  Rheumatology, 2010
• Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
  Arthritis & Rheumatism, 2009